Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, is ramping up its investments in India’s fast-growing healthcare market, with a strategic focus on single-specialty hospitals and contract drug manufacturers. The life sciences investment arm, which manages assets for the Novo Nordisk Foundation, had €142 billion ($165.6 billion) under management Continue Reading
